Title
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report

Permalink
https://escholarship.org/uc/item/9dk0n62k

Journal
Dermatology Online Journal, 23(1)

ISSN
1087-2108

Authors
Mitre, Victoria
Applebaum, Danielle S
Potenziani, Silvia
et al.

Publication Date
2017-01-01

License
CC BY-NC-ND 4.0

Peer reviewed
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report

Victoria Mitre¹, Danielle S. Applebaum¹, Silvia Potenziani², Sylvia Hsu¹

Affiliations: ¹ Baylor College of Medicine, Department of Dermatology, ² Baylor College of Medicine, Department of Pathology

Corresponding Author: Victoria Mitre One Baylor Plaza Baylor College of Medicine Houston, TX 77030 Email: victoria.mitre@bcm.edu

Abstract

Kaposi sarcoma (KS) is a multifocal angioproliferative tumor of endothelial origin. Despite nearly identical clinical and histopathologic presentations, KS is classified into four distinct varieties: classic/sporadic, AIDS-associated, African/endemic, and iatrogenic. All subtypes are invariably linked to human herpesvirus-8 (HHV-8) and show a male predilection. Classic Kaposi sarcoma is exceedingly rare in the Asian population and its incidence varies by region and ethnic group predominance. A study in the Xinjiang region of China found that only 1% of classic KS cases occurred in patients belonging to the Han Chinese ethnic group, which formulates 84% of the Taiwanese population. Therefore, classic KS is extremely rare in Taiwan, with very few reports describing the manifestations of disease in this population. We report a case of an immunocompetent 68-year-old HIV-negative Han Chinese man born and raised in Taiwan with classic Kaposi sarcoma on his trunk and extremities.

Keywords: classic Kaposi sarcoma; Han Chinese; HIV-negative; Taiwan

Introduction

Kaposi sarcoma (KS) is an angioproliferative spindle cell tumor of endothelial origin first described in 1872 by Moritz Kaposi [1-5]. Before 1981, KS was considered an uncommon disease in the United States, primarily affecting elderly men of Eastern European, Jewish, and Mediterranean descent. Today this is known as the classic variant, which follows an indolent course [1, 5-7]. Classic Kaposi sarcoma presents in the lower limbs and feet in 85-98% of patients [5, 7, 8], with trunk involvement in 9-15% of patients [7, 8] and very rare involvement of the viscera, lymph nodes, and oral cavity [1, 5-7]. Classic Kaposi sarcoma is very rare in the Asian population. In the Xinjiang region of China, 87% of cases of classic KS occurred in patients in the Uyghur ethnic group and only 1% in the Han Chinese ethnic group, although each compose approximately 40% of the population in the region [7]. People in the Han Chinese ethnic group populate 84% of Taiwan [9]. Therefore, it is not surprising that classic KS is extremely rare in Taiwan, with very few reports describing the manifestations of disease in this population [6, 10].

Case Synopsis

A 68-year-old immunocompetent HIV-negative Han Chinese man born and raised in Taiwan presented with a six-month history of lesions on his trunk and upper extremities, and a five-year history of similar lesions on his lower extremities. He had a known history of non-insulin dependent diabetes mellitus, but was otherwise healthy.

Figure 1. Erythematous and violaceous papules, nodules, and plaques with lichenification on the bilateral feet and ankles.
Examination revealed multiple erythematous to violaceous plaques on his trunk and extremities, as well as lichenified purpuric papules, nodules, and plaques on his bilateral lower extremities. Additionally, he had painful bilateral lower extremity edema that reduced his mobility; he reported a ten-pound weight loss with associated lethargy over the past six months. A biopsy from his left upper back revealed a dermal infiltrate of atypical spindle cells with slit-like spaces and focal red blood cell extravasation. Histologically, the lesions were compatible with the characteristic plaque stage of Kaposi sarcoma. Immunohistochemical studies confirmed the lesion was HHV-8 positive and HIV screening was negative. A diagnosis of classic Kaposi sarcoma was made. Given the diffuse nature of his lesions, he was treated with five rounds of systemic liposomal doxorubicin and paclitaxel, which led to flattening of the lesions, improvement in lesion color, and complete resolution of edema. A sixth and final round of chemotherapy was not administered owing to marked improvement in his lesions and unfavorable side effects including nausea, vomiting, and weight loss.

**Case Discussion**

Kaposi sarcoma (KS) is a multicentric neoplasm of endothelial origin characterized by proliferation of spindle cells, angiogenesis, and inflammation [1, 4]. Despite nearly identical histopathologic and clinical
Before 1981 in the United States, KS was considered an uncommon disease, primarily affecting elderly men of Eastern European, Jewish, and Mediterranean descent. Today this is known as the classic variant, which follows an indolent course [1, 5-7]. Classic KS presents in the lower limbs and feet in 85-98% of patients [5, 7, 8], with trunk involvement in 9-15% of patients [7, 8], and very rare involvement of the viscera, lymph nodes, and oral cavity [1, 5-7]. Furthermore, lower extremity edema is seen in 20-30% of patients with classic KS [1, 7, 12]. Although pain is the most common presenting symptom, approximately 50% of people are asymptomatic at presentation [8]. Notably, an increased risk of classic KS has been reported in patients with diabetes mellitus [13].

Classic KS treatment primarily involves slowing disease progression. Given its often indolent course, clinical observation may be preferred for asymptomatic patients with early-stage lesions [14]. Local chemotherapy, immunotherapy, and radiotherapy are effective in treating limited disease. Among localized therapies, a ≥50% decrease in lesion size has been demonstrated in 62% of patients treated with intralesional vincristine, 50-90% treated with intralesional interferon-a2, and 56% treated with imiquimod [14]. Alitretinoin gel has demonstrated an overall response rate of 37% [15]. Radiotherapy has shown a complete response rate in 60-93% [14]. Additionally, surgical excision is limited to small, nodular lesions and has been associated with Koebner phenomenon [1, 14]. Systemic chemotherapies are reserved for disseminated and aggressive disease. Pegylated liposomal doxorubicin is frequently used as first-line therapy and has shown a ≥50% decrease in lesion size in 71-100% of cases [14, 16]. For other commonly used systemic therapies, a ≥50% reduction in lesion size has been documented in 58%-90% of patients for vinca-alkaloids, 74%-76% for etoposide, 93%-100% for taxanes, and 100% for gemcitabine [14].

The close association between HHV-8 and KS was first identified in 1994 using representational difference analysis. The major route of transmission is exposure to HHV-8-infected saliva in endemic areas, and sexual activity in non-endemic areas [17]. Human herpesvirus-8 prevalence varies between geographic
regions with the rates greater than 50% in sub-Saharan Africa, 20-30% in some Mediterranean countries, and less than 10% in most of Europe, the United States, and Asia [18]. Although the pathogenesis of Kaposi sarcoma remains unclear, HHV-8 infection has been found to be necessary but insufficient for the development of KS, likely requiring some degree of host immune dysfunction [11]. Human herpesvirus-8 induces an atypical differentiation of infected endothelial cells and promotes an endothelial-mesenchymal transition that increases invasiveness via cellular metalloproteinase MT1-MMP [19]. Human herpesvirus-8 infected cells secrete pro-angiogenic cytokines such as VEGFR3 [19]. Kaposi sarcoma lesions often develop in sites of trauma or in individuals with chronic inflammation, such as AIDS patients. These findings suggest that activation of inflammatory pathways or repair mechanisms increases the risk of KS tumor development in HHV-8-infected individuals. Thus, it appears that HHV-8 not only promotes inflammation by releasing inflammatory cytokines such as vIL6, but also benefits from inflammatory environments [19].

The histopathologic findings of Kaposi sarcoma vary by clinical stage [11]. The characteristic histopathologic features of KS appear in the plaque stage and include proliferation of vascular channels composed of collagen and reticulin fibers appearing as clefts between increased spindle cells. Extravasated red blood cells and hemosiderin-laden macrophages are often present, giving KS lesions their characteristic erythematous to violaceous hue [1, 11]. Clusters of variably sized eosinophilic hyaline globules may be seen within spindle cells and macrophages in an intracytoplasmic location or may be seen extracellularly. The plaque stage normally involves most of the dermis, exhibiting the same histologic features as the nodular stage [1]. A chronic inflammatory infiltrate, including lymphocytes, plasma cells, and dendritic cells, is often present in variable amounts [1, 11].

Immunohistochemistry of lesional cells in Kaposi sarcoma reveals expression of vascular, lymphatic, and mesenchymal markers. Lymphatic markers include D2-40, LYVE-1, Prox-1, and VEGFR3 [11, 20]. Endothelial markers include factor VIII-related antigen, CD31 (PECAM-1), and CD34, with factor CD34 present in the more advanced-stage lesions of KS [11]. Mesenchymal markers include vimentin and PDGFRα [20]. HHV-8 immunohistochemical stain is the most diagnostically sensitive and specific marker for KS diagnosis and targets a latency associated nuclear antigen-1 (LANA-1), which is a key HHV-8 gene product essential for maintaining episomal viral DNA during latent infection and for regulating cell division [1, 11, 21].

Conclusion
Although classic Kaposi sarcoma remains exceedingly rare in the Asian population, our report suggests that KS should still be considered in the differential diagnosis of HIV-negative Asian patients.

References:


